| Family Clinic | |
|
3921 I 49 S Service Rd Opelousas LA 70570-0758 | |
| (337) 942-5706 | |
| (337) 942-2644 |
| Full Name | Family Clinic |
|---|---|
| Speciality | Family Medicine |
| Location | 3921 I 49 S Service Rd, Opelousas, Louisiana |
| Authorized Official Name and Position | Michael H Montgomery (PRESIDENT) |
| Authorized Official Contact | 3379425706 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Family Clinic 3921 I 49 S Service Rd Opelousas LA 70570-0758 Ph: (337) 942-5706 | Family Clinic 3921 I 49 S Service Rd Opelousas LA 70570-0758 Ph: (337) 942-5706 |
| NPI Number | 1023087749 |
|---|---|
| Provider Enumeration Date | 03/15/2006 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 0143225748 |
|---|---|
| Medicare Enrollment ID | O20061003000175 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023087749 | NPI | - | NPPES |
| 1941492 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Michael W Basile |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013986728 PECOS PAC ID: 7012953722 Enrollment ID: I20050705000387 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
| Provider Name | Latonya R Kelly |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063430213 PECOS PAC ID: 4688679590 Enrollment ID: I20060928000133 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
| Provider Name | Kevin N Guillory |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376740324 PECOS PAC ID: 5698847390 Enrollment ID: I20080711000138 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
| Provider Name | Laura Braham |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770552556 PECOS PAC ID: 7315132487 Enrollment ID: I20101115000896 |
News Archive
Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
News Archive
Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.
Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).
A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer.
Tessera, Inc., a Seattle-based biomedical company, has released its first product, ProstaMark EPCA (Early Prostate Cancer Antigen), as an Analyte Specific Reagent (ASR) for commercial use in pathology laboratories to assist pathologists in their efforts to determine if cancer is present in the prostate.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
Opelousas General Health System Physician Practices Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 827 N Union St, Opelousas, LA 70570 Phone: 337-948-1802 Fax: 337-942-9074 | |
Southwest Louisiana Primary Health Care Center, Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8762 Highway 182, Opelousas, LA 70570 Phone: 337-942-2005 Fax: 337-942-8644 | |
Alan J Sonsky Md Apmc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3975 I49 South Service Road, Suite 230, Opelousas, LA 70570 Phone: 337-948-7040 | |
Metoyer Medical Corporation Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 204 W North St, Opelousas, LA 70570 Phone: 337-948-4445 Fax: 337-948-1118 | |
Loyd H Boulet Jr Md A Professional Medical Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1270 Attakapas Dr, Opelousas, LA 70570 Phone: 337-942-6324 | |
Ochsner Clinic Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3975 I 49 S Service Rd Ste 205-a, Opelousas, LA 70570 Phone: 337-942-1151 Fax: 337-678-3339 |